Selected research
Industry Research
AI Clinical Trial Design Software Industry Research Report 2026
Market perspective
The global AI Clinical Trial Design Software market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AI Clinical Trial Design Software market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AI Clinical Trial Design Software market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AI Clinical Trial Design Software market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AI Clinical Trial Design Software include Cytel, TriNetX, Saama, Simulations Plus, Statsols, ConcertAI, Phesi, Faro Health and QuantHealth, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AI Clinical Trial Design Software market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AI Clinical Trial Design Software.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AI Clinical Trial Design Software Market by Company
Cytel
TriNetX
Saama
Simulations Plus
Statsols
ConcertAI
Phesi
Faro Health
QuantHealth
Unlearn
MMS
Berry Consultants
ZS
Clinion
Nurocor
Lindus Health
TrialKey
Protocol Builder
Medidata
IQVIA
Certara
AI Clinical Trial Design Software Segment by Type
End-to-End Trial Design Platforms
Protocol Authoring and Optimization Software
Trial Simulation and Outcome Prediction Software
Adaptive and Bayesian Design Software
Feasibility and Enrollment Design Software
Synthetic Control and Digital Twin Software
AI Clinical Trial Design Software Segment by Application
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Medical Device and Diagnostics Companies
Academic and Medical Research Institutions
Government and Nonprofit Research Organizations
Other Clinical Research Organizations
AI Clinical Trial Design Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Clinical Trial Design Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Clinical Trial Design Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Clinical Trial Design Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AI Clinical Trial Design Software companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- End-to-End Trial Design Platforms
- Protocol Authoring and Optimization Software
- Trial Simulation and Outcome Prediction Software
- Adaptive and Bayesian Design Software
- Feasibility and Enrollment Design Software
- Synthetic Control and Digital Twin Software
Applications
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Medical Device and Diagnostics Companies
- Academic and Medical Research Institutions
- Government and Nonprofit Research Organizations
- Other Clinical Research Organizations
Companies covered
- Cytel
- TriNetX
- Saama
- Simulations Plus
- Statsols
- ConcertAI
- Phesi
- Faro Health
- QuantHealth
- Unlearn
- MMS
- Berry Consultants
- ZS
- Clinion
- Nurocor
- Lindus Health
- TrialKey
- Protocol Builder
- Medidata
- IQVIA
- Certara
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AI Clinical Trial Design Software by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 End-to-End Trial Design Platforms
- 2.2.3 Protocol Authoring and Optimization Software
- 2.2.4 Trial Simulation and Outcome Prediction Software
- 2.2.5 Adaptive and Bayesian Design Software
- 2.2.6 Feasibility and Enrollment Design Software
- 2.2.7 Synthetic Control and Digital Twin Software
- 2.3 AI Clinical Trial Design Software by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical and Biotechnology Companies
- 2.3.3 Contract Research Organizations
- 2.3.4 Medical Device and Diagnostics Companies
- 2.3.5 Academic and Medical Research Institutions
- 2.3.6 Government and Nonprofit Research Organizations
- 2.3.7 Other Clinical Research Organizations
- 2.4 Assumptions and Limitations
3 AI Clinical Trial Design Software Breakdown Data by Type
- 3.1 Global AI Clinical Trial Design Software Historic Market Size by Type (2021-2026)
- 3.2 Global AI Clinical Trial Design Software Forecasted Market Size by Type (2027-2032)
4 AI Clinical Trial Design Software Breakdown Data by Application
- 4.1 Global AI Clinical Trial Design Software Historic Market Size by Application (2021-2026)
- 4.2 Global AI Clinical Trial Design Software Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AI Clinical Trial Design Software Market Perspective (2021-2032)
- 5.2 Global AI Clinical Trial Design Software Growth Trends by Region
- 5.2.1 Global AI Clinical Trial Design Software Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AI Clinical Trial Design Software Historic Market Size by Region (2021-2026)
- 5.2.3 AI Clinical Trial Design Software Forecasted Market Size by Region (2027-2032)
- 5.3 AI Clinical Trial Design Software Market Dynamics
- 5.3.1 AI Clinical Trial Design Software Industry Trends
- 5.3.2 AI Clinical Trial Design Software Market Drivers
- 5.3.3 AI Clinical Trial Design Software Market Challenges
- 5.3.4 AI Clinical Trial Design Software Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AI Clinical Trial Design Software Players by Revenue
- 6.1.1 Global Top AI Clinical Trial Design Software Players by Revenue (2021-2026)
- 6.1.2 Global AI Clinical Trial Design Software Revenue Market Share by Players (2021-2026)
- 6.2 Global AI Clinical Trial Design Software Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AI Clinical Trial Design Software Head Office and Area Served
- 6.4 Global AI Clinical Trial Design Software Players, Product Type & Application
- 6.5 Global AI Clinical Trial Design Software Manufacturers Established Date
- 6.6 Global AI Clinical Trial Design Software Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AI Clinical Trial Design Software Market Size (2021-2032)
- 7.2 North America AI Clinical Trial Design Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AI Clinical Trial Design Software Market Size by Country (2021-2026)
- 7.4 North America AI Clinical Trial Design Software Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AI Clinical Trial Design Software Market Size (2021-2032)
- 8.2 Europe AI Clinical Trial Design Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AI Clinical Trial Design Software Market Size by Country (2021-2026)
- 8.4 Europe AI Clinical Trial Design Software Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AI Clinical Trial Design Software Market Size (2021-2032)
- 9.2 Asia-Pacific AI Clinical Trial Design Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AI Clinical Trial Design Software Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AI Clinical Trial Design Software Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AI Clinical Trial Design Software Market Size (2021-2032)
- 10.2 South America AI Clinical Trial Design Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AI Clinical Trial Design Software Market Size by Country (2021-2026)
- 10.4 South America AI Clinical Trial Design Software Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AI Clinical Trial Design Software Market Size (2021-2032)
- 11.2 Middle East & Africa AI Clinical Trial Design Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AI Clinical Trial Design Software Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AI Clinical Trial Design Software Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Cytel
- 12.1.1 Cytel Company Information
- 12.1.2 Cytel Business Overview
- 12.1.3 Cytel Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.1.4 Cytel AI Clinical Trial Design Software Product Portfolio
- 12.1.5 Cytel Recent Developments
- 12.2 TriNetX
- 12.2.1 TriNetX Company Information
- 12.2.2 TriNetX Business Overview
- 12.2.3 TriNetX Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.2.4 TriNetX AI Clinical Trial Design Software Product Portfolio
- 12.2.5 TriNetX Recent Developments
- 12.3 Saama
- 12.3.1 Saama Company Information
- 12.3.2 Saama Business Overview
- 12.3.3 Saama Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.3.4 Saama AI Clinical Trial Design Software Product Portfolio
- 12.3.5 Saama Recent Developments
- 12.4 Simulations Plus
- 12.4.1 Simulations Plus Company Information
- 12.4.2 Simulations Plus Business Overview
- 12.4.3 Simulations Plus Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.4.4 Simulations Plus AI Clinical Trial Design Software Product Portfolio
- 12.4.5 Simulations Plus Recent Developments
- 12.5 Statsols
- 12.5.1 Statsols Company Information
- 12.5.2 Statsols Business Overview
- 12.5.3 Statsols Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.5.4 Statsols AI Clinical Trial Design Software Product Portfolio
- 12.5.5 Statsols Recent Developments
- 12.6 ConcertAI
- 12.6.1 ConcertAI Company Information
- 12.6.2 ConcertAI Business Overview
- 12.6.3 ConcertAI Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.6.4 ConcertAI AI Clinical Trial Design Software Product Portfolio
- 12.6.5 ConcertAI Recent Developments
- 12.7 Phesi
- 12.7.1 Phesi Company Information
- 12.7.2 Phesi Business Overview
- 12.7.3 Phesi Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.7.4 Phesi AI Clinical Trial Design Software Product Portfolio
- 12.7.5 Phesi Recent Developments
- 12.8 Faro Health
- 12.8.1 Faro Health Company Information
- 12.8.2 Faro Health Business Overview
- 12.8.3 Faro Health Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.8.4 Faro Health AI Clinical Trial Design Software Product Portfolio
- 12.8.5 Faro Health Recent Developments
- 12.9 QuantHealth
- 12.9.1 QuantHealth Company Information
- 12.9.2 QuantHealth Business Overview
- 12.9.3 QuantHealth Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.9.4 QuantHealth AI Clinical Trial Design Software Product Portfolio
- 12.9.5 QuantHealth Recent Developments
- 12.10 Unlearn
- 12.10.1 Unlearn Company Information
- 12.10.2 Unlearn Business Overview
- 12.10.3 Unlearn Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.10.4 Unlearn AI Clinical Trial Design Software Product Portfolio
- 12.10.5 Unlearn Recent Developments
- 12.11 MMS
- 12.11.1 MMS Company Information
- 12.11.2 MMS Business Overview
- 12.11.3 MMS Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.11.4 MMS AI Clinical Trial Design Software Product Portfolio
- 12.11.5 MMS Recent Developments
- 12.12 Berry Consultants
- 12.12.1 Berry Consultants Company Information
- 12.12.2 Berry Consultants Business Overview
- 12.12.3 Berry Consultants Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.12.4 Berry Consultants AI Clinical Trial Design Software Product Portfolio
- 12.12.5 Berry Consultants Recent Developments
- 12.13 ZS
- 12.13.1 ZS Company Information
- 12.13.2 ZS Business Overview
- 12.13.3 ZS Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.13.4 ZS AI Clinical Trial Design Software Product Portfolio
- 12.13.5 ZS Recent Developments
- 12.14 Clinion
- 12.14.1 Clinion Company Information
- 12.14.2 Clinion Business Overview
- 12.14.3 Clinion Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.14.4 Clinion AI Clinical Trial Design Software Product Portfolio
- 12.14.5 Clinion Recent Developments
- 12.15 Nurocor
- 12.15.1 Nurocor Company Information
- 12.15.2 Nurocor Business Overview
- 12.15.3 Nurocor Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.15.4 Nurocor AI Clinical Trial Design Software Product Portfolio
- 12.15.5 Nurocor Recent Developments
- 12.16 Lindus Health
- 12.16.1 Lindus Health Company Information
- 12.16.2 Lindus Health Business Overview
- 12.16.3 Lindus Health Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.16.4 Lindus Health AI Clinical Trial Design Software Product Portfolio
- 12.16.5 Lindus Health Recent Developments
- 12.17 TrialKey
- 12.17.1 TrialKey Company Information
- 12.17.2 TrialKey Business Overview
- 12.17.3 TrialKey Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.17.4 TrialKey AI Clinical Trial Design Software Product Portfolio
- 12.17.5 TrialKey Recent Developments
- 12.18 Protocol Builder
- 12.18.1 Protocol Builder Company Information
- 12.18.2 Protocol Builder Business Overview
- 12.18.3 Protocol Builder Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.18.4 Protocol Builder AI Clinical Trial Design Software Product Portfolio
- 12.18.5 Protocol Builder Recent Developments
- 12.19 Medidata
- 12.19.1 Medidata Company Information
- 12.19.2 Medidata Business Overview
- 12.19.3 Medidata Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.19.4 Medidata AI Clinical Trial Design Software Product Portfolio
- 12.19.5 Medidata Recent Developments
- 12.20 IQVIA
- 12.20.1 IQVIA Company Information
- 12.20.2 IQVIA Business Overview
- 12.20.3 IQVIA Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.20.4 IQVIA AI Clinical Trial Design Software Product Portfolio
- 12.20.5 IQVIA Recent Developments
- 12.21 Certara
- 12.21.1 Certara Company Information
- 12.21.2 Certara Business Overview
- 12.21.3 Certara Revenue in AI Clinical Trial Design Software Business (2021-2026)
- 12.21.4 Certara AI Clinical Trial Design Software Product Portfolio
- 12.21.5 Certara Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst